Pregabalin Capsule
Product Images NDC 72162-1545

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 72162-1545). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Lbl721621545)

Each capsule contains Pregabalin, USP 150mg and NDC 72162-1545-9. It is given as a prescription drug and should be kept out of reach of young children. The drug should be stored at a temperature between 20°- 25°C (68°-77°F). The drug is manufactured by ScieGen Pharmaceuticals Inc and repackaged by Bryant Ranch Prepack, Inc. The quantity provided is 90 capsules.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

This text seems to be part of a data analysis report related to medical patients. It shows the percentage of patients whose condition has improved, represented by the numbers "8 8 8 8 8 3 88 8" and an additional value of "3". The following lines and symbols may indicate further data, but due to errors and a lack of context, their meaning is unclear.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

This appears to be a chart or graph showing the percentage of patients who improved after taking Pregabalin 160 mg for three days. The chart also includes some numbers which may reflect the level of pain improvement from a baseline. However, the overall content and context is not clear, so it is difficult to provide a more detailed description or interpretation.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

FDA Label Image

Figure 4 (Pregabalin Fig04)

FDA Label Image

Figure 5 (Pregabalin Fig05)

The text contains information about the dosage of drugs - Fregabalin and Pregataiin, as well as Placebo taken by the patients. It also mentions the "percentage of improvement" in patients' pain from baseline. However, the information is not presented clearly and may be incomplete or incorrect.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

The text provided contains study titles, dosages for placebo and medication, and a statement that the medication was statistically significant compared to placebo. No other useful information is given.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

FDA Label Image

Figure 9 (Pregabalin Fig08)

The text provides a graph showing the percentage of patients who improved regarding pain management while using Pregabalin at doses of 300mg and 450mg per day and S0 Placebo. The graph measures the percent improvement in pain from baseline on the horizontal axis, ranging from 20 to 280. The vertical axis indicates the percentage of patients that experienced pain relief or improvement in their condition through the different drug doses.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

This appears to be a table showing the estimated percentage of subjects without LTR (not sure what LTR stands for) for Progabain and Placebo on different days. The percentages range from 0% to 100%.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

FDA Label Image

Figure 12 (Pregabalin Fig11)

This appears to be a chart or table showing the percent of subjects who improved over the course of 16 weeks on either Pregabalin or a Placebo. The numbers on the left-hand side represent the percentage of subjects improved, with 100% being the lowest number listed. The numbers on the top represent the different time points at which improvement was measured. The chart appears to be split into two columns, with Pregabalin on the left and Placebo on the right. The numbers listed in the body of the chart likely represent specific percentages of improvement achieved by subjects at different time points throughout the study.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

This is a medical formula to estimate the patient's creatinine clearance rate (CLCT), which is a measure of kidney function. The formula uses the patient's age, weight, and serum creatinine level. The result is adjusted for female patients by multiplying with 0.85. However, the text has some nonsensical characters that represent missing information.*

FDA Label Image

Chemical Structure (Pregabalin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.